Separately, Zacks Investment Research downgraded shares of Twist Bioscience from a hold rating to a sell rating in a report on Saturday, October 5th.
TWST opened at $26.00 on Wednesday. The company has a current ratio of 7.18, a quick ratio of 6.96 and a debt-to-equity ratio of 0.03. The company’s fifty day moving average price is $23.37 and its two-hundred day moving average price is $26.51. Twist Bioscience has a 1-year low of $13.99 and a 1-year high of $35.95. The company has a market cap of $806.04 million, a price-to-earnings ratio of -1.02 and a beta of 0.82.
In other news, CTO Bill Peck sold 19,553 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $30.06, for a total value of $587,763.18. Also, insider Patrick John Finn sold 36,932 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $23.83, for a total transaction of $880,089.56. In the last quarter, insiders sold 258,170 shares of company stock valued at $6,556,041. Company insiders own 29.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank bought a new position in Twist Bioscience in the 2nd quarter valued at $305,000. Conestoga Capital Advisors LLC acquired a new stake in shares of Twist Bioscience in the second quarter valued at $276,000. K.J. Harrison & Partners Inc acquired a new stake in shares of Twist Bioscience in the second quarter valued at $435,000. Wells Fargo & Company MN grew its stake in Twist Bioscience by 145.8% during the 2nd quarter. Wells Fargo & Company MN now owns 12,428 shares of the company’s stock worth $360,000 after purchasing an additional 7,372 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Twist Bioscience by 90.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,997,857 shares of the company’s stock worth $56,220,000 after purchasing an additional 947,399 shares in the last quarter. Hedge funds and other institutional investors own 47.74% of the company’s stock.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
See Also: What is the definition of market timing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.